NORTH CHICAGO, Ill., Aug. 25, 2020 /PRNewswire/ -- AbbVie(NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis. AbbVie also submitted an application to the European Medicines Agency (EMA) for RINVOQ earlier this year for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.
"Ankylosing spondylitis is a debilitating disease that can cause severe pain, restricted mobility and lasting structural damage. With limited treatment options, innovation is crucial to help more patients living with active ankylosing spondylitis reach their treatment goals," said Michael Severino, M.D., vice chairman and president, AbbVie. "RINVOQ has the potential to improve care by helping to provide disease control, addressing pain and improving function. We look forward to working with regulatory authorities and hope to bring this important treatment option to patients."
The applications to the FDA and EMA are supported by data from SELECT-AXIS 1, a Phase 2/3 study in which RINVOQ demonstrated significant improvements in signs and symptoms in patients with active ankylosing spondylitis.1 In this study, twice as many patients receiving RINVOQ (52 percent) met the primary endpoint of Assessment of SpondyloArthritis International Society (ASAS) 40 response versus placebo (26 percent) at week 14 (p<0.001).1 The safety profile of RINVOQ in ankylosing spondylitis was consistent with previously reported studies across therapeutic areas, including rheumatoid arthritis, atopic dermatitis and psoriatic arthritis, with no new significant safety risks detected.2-4
Ankylosing spondylitis is a chronic, progressive, inflammatory musculoskeletal disease impacting more than five million people worldwide.5,6 The range of symptoms pose significant physical, psychological and economic burden on individuals impacted by the disease.5,7-9
About RINVOQ (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.10-17 In August 2019, RINVOQ received U.S. FDA approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ was approved by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. The approved dose for RINVOQ in rheumatoid arthritis is 15 mg. Phase 3 trials of RINVOQ in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn's disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing.12-17 Use of RINVOQ in ankylosing spondylitis is not approved and its safety and efficacy have not been established by regulatory authorities.
Important Safety Information about RINVOQ (upadacitinib)18
RINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.
What is the most important information I should know about RINVOQ?RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.
What should I tell my HCP BEFORE starting RINVOQ?Tell your HCP if you:
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.
What should I tell my HCP AFTER starting RINVOQ?Tell your HCP right away if you:
What are the common side effects of RINVOQ?These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.
RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.
This is the most important information to know about RINVOQ. For more information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. Please click here for theFull Prescribing InformationandMedication Guide. Globally, prescribing information varies; refer to the individual country product label for complete information.
About AbbVie in Rheumatology
For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals. For more information on AbbVie in rheumatology, visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie on Twitter,Facebook,Instagram,YouTubeandLinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
View original content:http://www.prnewswire.com/news-releases/abbvie-submits-regulatory-application-to-fda-for-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis-301117875.html
SOURCE AbbVie
See the article here:
AbbVie Submits Regulatory Application to FDA for RINVOQ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis - BioSpace
- The Compression Fracture of Thoracic Spine Due to Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis: A Case Report - Cureus - February 15th, 2025
- Rheumatoid arthritis tied to cognitive decline in dementia - Medical Xpress - February 15th, 2025
- Tools and Devices to Improve Life and Mobility With Arthritis - U.S. News & World Report - February 15th, 2025
- Actor Adam Thomas Reveals How 'Eating Nothing But Meat and Eggs' is Easing his Arthritis Pain But These Are the Risks - Men's Health UK - February 15th, 2025
- New insights into the association between arthritis and overactive bladder in NHANES 20052020 - Nature.com - February 15th, 2025
- Rheumatoid Arthritis Treatment Market to Hit US$ 79.1 Billion - openPR - February 15th, 2025
- Psoriatic Disease, TNF Inhibitors, and Risk of Major Adverse Events - Medpage Today - February 15th, 2025
- The best treatments for arthritic knees if you want to avoid knee replacement surgery - The Telegraph - February 15th, 2025
- Early Launch Metrics Indicate UCBs Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market - GlobeNewswire - February 15th, 2025
- Rosnilimab shows promise in rheumatoid arthritis trial - Investing.com - February 15th, 2025
- 5 foods that keep your joints strong and healthy - Mint - February 15th, 2025
- If You Have Arthritis, This New Makeup Brand Is for You - Money Talks News - February 15th, 2025
- Lower Your Risk Of Rheumatoid Arthritis With These 5 Basic Habits - mindbodygreen - February 15th, 2025
- 'I treat top athletes with arthritis - cupboard staple ingredients are quite effective for pain and swelling' - GB News - February 15th, 2025
- AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - Yahoo - February 15th, 2025
- Rheumatology enters the chat: research projects use AI and collaborative thinking to improve patient care - University of Alberta - February 15th, 2025
- In Patients with HS, a Closer Look at Stigmatization and Perceived Health Status - Medpage Today - February 15th, 2025
- Psoriatic Arthritis Treatment Market is Set To Fly High in Years to Come: AbbVie Inc., Amgen Inc., Johnson & - EIN News - February 15th, 2025
- Sandoz Rolls Out Rival Version Of AbbVie's Arthritis Drug Humira - BW Healthcare World - February 15th, 2025
- GSK To Bounce Regulatory Submissions For Experimental Arthritis Drug - BW Healthcare World - February 15th, 2025
- Living With Arthritis: Health Information Basics for You and Your ... - January 27th, 2025
- Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take - January 27th, 2025
- Rheumatoid Arthritis | Health Topics | NIAMS - January 27th, 2025
- 6 Things to Know About Psoriatic Arthritis - Hartford HealthCare - January 27th, 2025
- MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway - Nature.com - January 27th, 2025
- Rheumatoid Arthritis Basics: Overview, Symptoms, and Causes - January 27th, 2025
- 8 Things You Should Do in Your 20s, 30s, and 40s to Prevent Joint Pain Later in Life - Self - January 27th, 2025
- 8 Natural Remedies to Relieve Join Pain and Improve Mobility - Health.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KTRE - January 27th, 2025
- Research Shows a Link Between Inflammation in the Gut and Rheumatoid Arthritis - Health Central - January 27th, 2025
- Address to the Business Community Attend the Arthritis Foundation Event - TAPinto.net - January 27th, 2025
- The journey of 2-year-old with arthritis - PAHomePage.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KLTV - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo Lifestyle UK - January 27th, 2025
- Living with arthritis: Here's how diet, exercise, and daily habits can ease the pain - Moneycontrol - January 27th, 2025
- Sichuan wildlife park peddles tiger urine, claiming efficacy for rheumatoid arthritis, other conditions - Global Times - January 27th, 2025
- Non-surgical option to ease knee arthritis - The Week - January 27th, 2025
- Ease arthritis pain by adding 1 juice to your diet - Surrey Live - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo News UK - January 27th, 2025
- Drinking one juice can ease arthritis pain, studies reveal - Daily Record - January 27th, 2025
- Annual Health Observances | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - October 6th, 2024
- Obesity dampens rheumatoid arthritis treatment effectiveness, satisfaction - Healio - October 6th, 2024
- Patient Perspectives: Finding Grace While Living With Rheumatoid Arthritis - Rheumatology Advisor - October 6th, 2024
- Rheumatoid arthritis tied to heavy economic and human burdens - Medical Xpress - October 6th, 2024
- Dual therapy can have synergistic effect in difficult-to-treat inflammatory diseases - Healio - October 6th, 2024
- Hand-Held Scanner Could Transform Cancer and Arthritis Diagnosis - Technology Networks - October 6th, 2024
- Medical imaging breakthrough could transform cancer and arthritis diagnosis - University College London - October 6th, 2024
- Citryll and leading rheumatology centres receive - GlobeNewswire - October 6th, 2024
- Its going to be ubiquitous: Weight loss drugs may aid rheumatic disease treatment - Healio - October 6th, 2024
- Comorbidities Associated With Psoriasis: 5 Things to Know - Medscape - October 6th, 2024
- Opinion: Let's treat arthritis with the seriousness it deserves - Vancouver Sun - October 6th, 2024
- New handheld scanner technology could transform cancer and arthritis diagnosis - The Engineer - October 6th, 2024
- Stem cell therapy for osteoarthritis: Functional cartilage regeneration using 3d bioprinting technology - Open Access Government - October 6th, 2024
- Handheld scanner could transform cancer and arthritis diagnosis study - The Independent - October 6th, 2024
- Ankylosing Spondylitis and Self-Care: 6 Science-Backed Tips - Everyday Health - October 6th, 2024
- From a Labrador with arthritis to a goldfishs lifespan your pet queries answered... - The Sun - October 6th, 2024
- 15 Home Essentials That Make Life Easier If You Have Arthritis - HuffPost - September 21st, 2024
- Gout, a painful form of arthritis, is on the rise. Avoiding red meat and alcohol can help. - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pain - MedicineNet - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - U.S. News & World Report - September 21st, 2024
- Arthritis can flare up in colder weather: Tips to easing the pan - Medical Xpress - September 21st, 2024
- See how Waymo is bringing Arthritis Foundation of Arizona families to the ballpark - ABC15 Arizona in Phoenix - September 21st, 2024
- Prevalence of Loneliness in Inflammatory Arthritis and its Association with Disease Activity - Physician's Weekly - September 21st, 2024
- Psoriatic Arthritis and Gluten: Whats the Link? - Health Central - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Southernminn.com - September 21st, 2024
- 6 Knee Injuries That Can Cause Arthritis - Health News Hub - September 21st, 2024
- The Best Rheumatoid Arthritis Self-Care Tips To Soothe Painful Joints and Improve Mobility - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - El Paso Inc. - September 21st, 2024
- Shifting kneecap in kids? Early ligament repair can prevent arthritis in young Age: Experts - The Times of India - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Shelbynews - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Citizentribune - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - News-Daily.com - September 21st, 2024
- Casavant: Access to virtual care at risk for millions of arthritis patients - Daily Independent - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Avery Journal Times - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - The Elkhart Truth - September 21st, 2024
- What To Eat (And Skip) on a Rheumatoid Arthritis Diet To Reduce Painful Inflammation - Woman's World - September 21st, 2024
- Tiny knee bone linked to arthritis may have helped humans walk upright, scientists suggest - Sky News - September 13th, 2024
- Medical Marijuana Helps People With Arthritis And Other Rheumatic Conditions Reduce Use Of Opioids And Other Medications, Study Shows - Marijuana... - September 13th, 2024
- My 'stomach bug' turned out to be an agonising pain condition that left me wheelchair bound within four years - Daily Mail - September 13th, 2024
- Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis - Nature.com - September 13th, 2024